M&A | Nanologica

Nanologica AB (publ) Acquires Ardena Södertälje AB

29 January, 2026

Nanologica AB (publ) ("Nanologica") has today entered into an agreement and completed the acquisition of all shares in Ardena Södertälje AB ("Syntagon") from Ardena Sweden (the "Seller"). The purchase price amounts to approximately SEK 8.6 million and will be paid in the form of newly issued shares in Nanologica. Syntagon is a Contract Development and Manufacturing Organization with just over 45 employees, which in 2025 had sales of approximately SEK 80 million. Nanologica believes that

Nanologica AB (publ) förvärvar Ardena Södertälje AB

29 January, 2026

Nanologica AB (publ) (”Nanologica”) har idag ingått avtal om och genomfört förvärv av samtliga aktier i Ardena Södertälje AB (”Syntagon”) från Ardena Sweden (”Säljaren”). Köpeskillingen uppgår till ca 8,6 MSEK och erläggs i form av nyemitterade aktier i Nanologica. Syntagon är en Contract Development and Manufacturing Organization med drygt 45 anställda som under 2025 omsatte ca 80 MSEK. Nanologica gör bedömningen att förvärvet kommer att bidra positivt till koncernens resultat redan under 2026. Förvärvet stärker

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.